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Associations of statin use 
with motor performance and 
myalgia may be modified by 
25-hydroxyvitamin D: findings from 
a British birth cohort
Nikhil Sharma  , Rachel Cooper, Diana Kuh & Imran Shah
The objective was to examine whether: (1) statin use was associated with muscle related outcomes 
at age 60–64, (2) these associations were modified by 25-hydroxyvitamin D (25(OH)D) status and 
explained by inflammation, body-size or lifestyle in a British birth cohort. Markers of myalgia (intrusive 
body pain) and myopathy (self-reported and performance-based measures) were examined in 734 
men and 822 women (MRC National Survey of Health and Development). Statin use was associated 
with intrusive body pain, difficulty climbing stairs and slower chair rise speed. Some associations 
were modified by 25(OH)D e.g. the association with intrusive body pain was evident in the insufficient 
(13–20 ng/l) and deficient (<13 ng/l) 25(OH)D status groups (OR = 2.6,95% CI 1.7–1.1; OR = 1.8,95% 
CI 1.2–2.8, respectively) but not in those with status >20 ng/l (OR = 0.8,95% CI 0.5–1.4) (p = 0.003 for 
interaction). Associations were maintained in fully adjusted models of intrusive body pain and difficulty 
climbing stairs, but for chair rise speed they were fully accounted for by inflammation, body-size and 
lifestyle. In a nationally representative British population in early old age, statin use was associated 
with lower limb muscle-related outcomes, and some were only apparent in those with 25(OH)D status 
below 20 ng/l. Given 25(OH)D is modifiable in clinical practice, future studies should consider the links 
between 25(OH)D status and muscle related outcomes.
There is clear and compelling evidence that statins have a beneficial effect on cardiovascular risk factors1,2. This 
is reflected in recent guidelines from NICE3 that suggest that statins should be prescribed to anyone with a 10% 
ten-year risk of a cardiovascular event. As a result, approximately one-quarter of the population aged between 30 
and 85 years old could be prescribed a statin. However, there remain serious concerns about the potential adverse 
effects of statins if prescribed to such a large population4,5.
There is a discrepancy between the data from randomised controlled trials (RCT) and observational studies, 
therefore the incidence of adverse effects of statins continues to be debated6. Data from large randomised con-
trolled trials (RCT) suggest that adverse effects are similar to placebo. In a review of the trial data, Finegold (2014) 
concluded that only a minority of symptoms were genuinely due to statin use7. Nevertheless, it should be noted 
that the trials do not typically monitor for more indolent muscle conditions. For instance, the influential CTT 
collaboration meta-analysis of trials explored a small set of adverse effects that only included acute muscle con-
ditions (vascular events, cancers, rhabdomyolysis and deaths)1. As chronic muscle conditions have not generally 
been recorded in RCTs, it cannot be assumed that an absence of evidence is evidence of absence.
Observational studies of patients on statins typically focus on chronic muscle conditions and report a much 
higher rate of adverse effects than the RCTs. In a retrospective study of patients in routine care in Boston (USA), 
myalgia (muscle pain) and myopathy (muscle weakness) were the most commonly documented reasons for sta-
tin discontinuation, affecting 27% of patients8. Similarly, in a survey of over ten thousand statin users, a quarter 
of users reported muscle related side effects9. Cross sectional population data from the National Health and 
Nutrition Examination Survey (NHANES 1999–2002) suggest 22% of participants taking a statin reported 
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musco-skeletal pain compared with 18% participants not taking a statin10. Other large observational studies, 
some with up to 9 years of follow up11, report a higher prevalence of muscle related events in statin users com-
pared with non statin users12. Data from UK general practices are unclear; there are reports of an increased risk of 
moderate to severe myopathic events with statin use13 but other reports show no difference in myositis between 
statin users and non users14. The few studies to include measures of motor performance did not find an associ-
ation between statin use and reduced physical performance15–18 or response to physical training19. In both the 
clinical trials and observational studies there is little consistency in what constitutes a statin related adverse effect 
which makes direct comparison challenging.
There are many additional factors that could contribute to an increased risk of muscle related conditions 
in statin users compared with non users in observational studies. For instance, low 25-hydroxyvitamin D is 
prevalent in the UK population20,21 and is a cause of myopathy and myalgia. Previous studies report that low 
25-hydroxyvitamin D status may exacerbate musculoskeletal symptoms experienced with statin use22–24. Indeed, 
in a small series of 128 patients with statin induced myalgia, 25-hydroxyvitamin D was significantly lower in sta-
tin users than non users and responded positively to replacement in the majority of cases25. Overall this highlights 
the potential interaction between low 25-hydroxyvitamin D status and statin use in relation to adverse effects.
Higher body mass index, adverse lifestyle factors such as smoking, and socioeconomic conditions (SEC) are asso-
ciated with muscle-related outcomes and have been shown to be associated with 25-hydroxyvitamin D levels26,27. 
Statin users tend to have higher levels of inflammatory markers such as Interleukin 6 (IL-6) and C-reactive pro-
tein (CRP) and elevated levels of these markers have also been associated with poorer motor performance28, 
strength29, BMI30 and lifestyle31.
We investigated whether statin use was associated with a range of muscle related outcomes in a large nation-
ally representative British birth cohort of men and women followed up to early old age. We assessed intrusive 
body pain as a marker of myalgia. In addition, we used both self-reported and performance-based measures of 
limb function as markers of myopathy. We hypothesized that any association between statin use and these out-
comes would be modified by current 25-hydroxyvitamin D (based upon published data refs22–24) and accounted 
for by inflammatory status, prior body mass index (BMI) and osteoarthritis (OA), smoking and SEC32. Testing 
these hypotheses in a nationally representative British cohort addresses a significant gap within the literature that 
directly informs the implementation of the NICE guidelines.
Methods
Study population. The MRC National Survey of Health and Development (NSHD) has followed a nation-
ally representative sample, originally of 5,362 individuals, born in mainland Britain in March 1946. At the 23rd 
follow up at 60–64 years, study members first received postal questionnaires to complete and were then invited 
to attend one of six clinical research facilities (CRFs) or to have a research nurse visit their home33. Of the 3163 
people in the target sample, information was obtained from 2662 (84%) participants, of whom 2474 completed a 
postal questionnaire and 2229 had a clinical assessment (1690 at a CRF and 539 at home). No attempt was made 
to contact the remaining study members: 718 (13.4%) had already died, 594 (11.1%) had previously withdrawn 
from the study, 567 (10.6%) lived abroad and 320 (5.9%) had been untraceable for more than ten years. The study 
received ethical approval for the data collection at age 60–64 from the Central Manchester Local Research Ethics 
Committee and the Scotland A Research Ethics Committee and is compliant with the appropriate guidelines and 
regulations. Informed consent was provided by participants.
Intrusive Body pain. The definition of myalgia is broad. We used a question from the SF-36 (included on the 
postal questionnaire) that asked about intrusive body pain (based on how much the pain interfered with normal 
work including both work outside the home and housework)34. The data for responses were recoded from a scale 
of 0 (not at all) to 4 (extremely) into a binary variable which indicated if intrusive body pain was absent (0) or 
present (1–4).
Limb function. Muscle disorders predominantly affect the proximal muscle groups. We therefore used 
measures that represent proximal limb function and compared them with measures of distal limb function. 
Assessments of function were conducted during the clinical assessment at age 60–64 with trained nurses follow-
ing standardised protocols for the performance-based tests35.
Difficulties going up/down stairs. As a subjective indicator of proximal muscle function participants were 
asked if they had difficulty going up and down a flight of 12 stairs (coded Yes vs No)36.
Difficulties gripping heavy objects. Participants were asked if they had difficulty gripping heavy objects 
like a full kettle (coded Yes vs No). This was used as a subjective indicator of distal limb function.
Chair Rise speed. Chair rise speed was used as an objective indicator of proximal lower limb function. Chair 
rise speed per minute was calculated from the time taken to rise from a sitting to a standing position with straight 
back and legs, and then sit down again as fast as possible ten times (chair rise speed per minute = (10/chair rise 
time)*60). Where a test was not completed for reasons of poor health (n = 136), values were imputed as in previ-
ous analyses37,38, by taking the sex-specific mean of the bottom fifth.
Grip strength. Grip strength was used as an objective indicator of distal limb function and was measured 
isometrically using an electronic handgrip dynamometer39. The maximum strength achieved during 6 attempts 
(three in each hand) was used. Where a test was not completed for reasons of poor health (n = 49), values were 
imputed as in previous analyses37,38, by taking the sex-specific mean of the bottom fifth.
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Statin use. Study members were asked to report all regularly prescribed medications on the postal question-
naire and by the nurse at their clinical assessment. These reports were coded according to the British National 
Formulary (BNF) formulary and a variable denoting statin use (yes vs no) was derived.
Current 25-hydroxyvitamin D and inflammatory status. Overnight fasting blood samples were taken 
during the clinical assessment and initially processed at the CRF laboratories. Aliquots were frozen and stored 
prior to being transferred to the MRC Human Nutrition Research (HNR) laboratory in Cambridge where analy-
ses of CRP was processed according to standardised protocols40. Analyses of IL-6 and 25-hydroxyvitamin D were 
undertaken by the British Heart Foundation Research Centre in Glasgow (BHFRC) the latter using LC MS/MS 
(Liquid chromatography–mass spectrometry). Inflammatory markers were positively skewed and therefore trans-
formed using the natural logarithm to achieve normality of their distributions40 and used as continuous variables.
We carefully considered how to model 25-hydroxyvitamin D in these analyses and despite the acknowledged 
loss of statistical power we decided a priori to adopt a categorical approach for the following reasons. First, sup-
porting literature, particularly the guidelines for clinicians (for instance the US reference ranges41), typically con-
sider 25-hydroxyvitamin D as categories. Second, treating 25-hydroxyvitamin D as a continuous variable assumes 
interactions are linear and ignores the cellular42, observational43 and clinical44 evidence that supports a threshold 
effect of 25-hydroxyvitamin D status.
Therefore 25-hydroxyvitamin D levels were split into thirds; normal (>20 ng/l); insufficient (13–20 ng/l); and 
deficient (<13 ng/l). This is broadly similar to the US reference ranges (insufficient 25-hydroxyvitamin D is con-
sidered <12 ng/l). A priori, based upon published data22–24, we hypothesized that the effect of statin on the muscle 
outcomes would be exacerbated by low 25-hydroxyvitamin D.
Other covariates. We included those covariates that have been shown to be associated with the muscle out-
come variables in this cohort38,45 or others46,47 and which were also hypothesized to be associated with statin use.
We included knee OA given its importance to proximal lower limb performance and intrusive body pain and 
because it is also associated with statin use48. We used the American College of Rheumatology criteria for the 
clinical diagnosis of idiopathic knee OA age 53, namely knee pain in either knee on most days for at least 1 month 
in the last year and at least two of the following: stiffness, crepitus, bony tenderness and bony enlargement. These 
items were assessed through a clinical examination conducted by a trained research nurse; further details have 
been published elsewhere49.
Information on life time cigarette smoking up to age 60–64 was classified into three categories: never, former 
and current smoker. Height and weight were measured by the research nurse according to standard protocols at 
a home visit at age 53, and body mass index (BMI) was calculated (kg/m2). Own occupational class was chosen 
to represent adult SEC based on the study member’s occupation at age 53 (or at 43, 36 or 26 years if missing at 53 
years, n = 54). The Registrar General’s six-group social classification was collapsed into three groups: professional 
and intermediate (I and II); skilled non-manual (IIINM) or skilled manual (IIIM); and semi-skilled and unskilled 
manual (IV and V). The highest educational qualification obtained by age 26 was collapsed into three groups: 
degree level or advanced secondary qualifications (or equivalents); ordinary secondary level (or equivalents); no 
formal qualifications.
Statistical Analysis. All statistical analyses were conducted using R (R Foundation for Statistical 
Computing, Vienna, Austria. http://www.R-project.org/).
There were 1556 study members with complete data on all outcomes and covariates. The characteristics of 
these men and women were compared using chi-squared tests and analysis of variance (ANOVA) as appropriate. 
The associations of statin use and 25-hydroxyvitamin D status with each muscle outcome were investigated in the 
combined sample of men and women as there was no evidence for interactions between sex and statin use with 
any of the outcomes. We used logistic regression for binary outcomes (intrusive body pain, difficulty going up 
and down stairs and difficulty gripping) and linear regression for continuous outcomes (chair rise speed and grip 
strength). In the first set of models, we examined the associations of statin use and 25-hydroxyvitamin D with 
each of the muscle outcomes separately, adjusted only for sex. In the second set of models, we tested for interac-
tions between statin use and 25-hydroxyvitamin D status using likelihood ratio tests with 25-hydroxyvitamin D 
first modelled categorically and then rerun modelled continuously. This was to formally examine whether low 
25-hydroxyvitamin D exacerbated the risk of muscle related outcomes as hypothesized a priori. We then further 
adjusted the models in which 25-hydroxyvitamin D was modelled categorically for inflammatory factors, BMI 
and knee OA, and finally for smoking status and adult SEC.
In sensitivity analyses we compared the estimates from the sex adjusted models in the sample with complete 
data and in the samples (maximum n = 2380) for whom statin use and at least one muscle related outcome was 
known.
Transparency declaration. NS affirms that the manuscript is an honest, accurate, and transparent account 
of the study being reported and that no important aspects of the study have been omitted.
Data sharing statement. Bona fide researchers can apply to access the NSHD data via a standard appli-
cation procedure (further details available at: http://www.nshd.mrc.ac.uk/data.aspx doi:10.5522/NSHD/Q101; 
doi:10.5522/NSHD/Q102).
Results
A fifth of participants (19.9%) were taking statins (Table 1) with men more likely to be taking statins than women 
(Men 24.5%, Women 15.7%, Chi-squared test of sex difference p < 0.001). Compared with men, women reported 
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more intrusive body pain and, difficulties going up and down stairs and gripping heavy objects in addition to 
slower chair rise speed and weaker grip strength.
Compared with those not taking a statin, statin users reported more intrusive body pain and reduced proxi-
mal limb function (as indicated by slower chair rise speed and increased prevalence of reported difficultly going 
up/downstairs). Statin users also had higher mean levels of IL-6, higher mean BMI and were more likely to have 
knee OA (women only).
Intrusive Body Pain. Statin use, but not 25-hydroxyvitamin D, was associated with greater odds of reporting 
intrusive body pain (Table 2, Model A). There was evidence of an interaction (p = 0.003) between statin use and 
25-hydroxyvitamin D such that statin use was associated with greater odds of reporting intrusive body pain in the 
insufficient and deficient 25-hydroxyvitamin D groups but not in the normal group when 25-hydroxyvitamin D 
was modelled categorically (Model B). This interaction was also evident when 25-hydroxyvitamin D was mod-
elled continuously (see Fig. 1). The estimates for statin use in the insufficient and deficient 25-hydroxyvitamin 
D groups were increasingly attenuated after adjusting first for inflammation (Model C), then BMI and knee OA 
(Model D) and finally smoking and SEC (Model E); Statin use in the insufficient group remained associated with 
intrusive body pain in the fully adjusted model (OR = 1.9, 95% CI 1.2 to 3.1).
Limb function. Difficulty going up/down stairs. Statin use and being in the deficient 25-hydroxyvitamin 
D group were both associated with greater odds of difficulty going up/down stairs (Table 3 Model A). There 
was some evidence of an interaction between statin use and 25-hydroxyvitamin D (p = 0.078) such that statin 
Men Women
Men Women
No Statin Statin No Statin Statin
Total n in each group %
734 822 554 180 693 129
47.2 52.8 75.5 24.5 84.3 15.7
Outcomes
Intrusive body pain 32.6 43.6 30 40.6 41.3 55.8
Difficulty going up/down stairs 12.3 20.8 8.7 23.3 18.5 33.3
Difficulty gripping heavy objects 7.4 28.5 6.5 10 28.1 30.2
Chair Rise Speed (stands/min) 26.1 25.3 26.5 25 25.6 23.6
SD (7.1) (8.3) (7.1) (7.1) (8.5) (6.9)
Grip Strength max of 6 (kg) 45.3 24.7 45.4 44.9 24.8 24.3
SD (11.9) (7.9) (12.2) (11.1) (8) (7.9)
Inflammatory Markers & 25-hydroxyvitamin D
IL6 (log pg/ml) 0.7 0.7 0.7 0.9 0.6 0.9
SD (0.7) (0.7) (0.7) (0.7) (0.7) (0.6)
CRP (log mg/l) 0.8 0.8 0.7 0.8 0.8 0.9
SD (0.8) (0.9) (0.8) (0.9) (0.9) (0.8)
25-hydroxyvitamin D
 Normal >20 ng/l 30.4 33.5 32.3 24.4 34.3 28.7
 Insufficient 13–20 ng/l 34.2 33.6 32.7 38.9 32 41.9
 Deficient <13 ng/l 35.4 33 35 36.7 33.6 29.5
Covariates
BMI age 53 (kg/m2) 27.2 26.9 26.7 28.7 26.5 29.4
SD (3.7) (5) (3.5) (4) (4.6) (6.2)
Knee OA at 53 (Yes) 6.1 11.6 5.2 8.9 10.2 18.6
Education (by 26 years)
 None or Sub-GCE 35.4 38.1 32.1 45.6 36.2 48.1
 O-level 14.7 28.1 14.8 14.4 28 28.7
 A level/Degree or higher 49.9 33.8 53.1 40 35.8 23.3
SEC (age 53)
 I or II 57.1 40.1 58.1 53.9 41 35.7
 IIINM or IIIM 32.8 43.7 31.6 36.7 44.2 41.1
 IV or V 10.1 16.2 10.3 9.4 14.9 23.3
Cigarette Smoking
 Current 10.5 11.6 11 8.9 10.4 17.8
 Exsmoker 60.9 53.8 58.7 67.8 54.4 50.4
 Never 28.6 34.7 30.3 23.3 35.2 31.8
Table 1. Characteristics of the sample of 1556 men and women in the MRC National Survey of Health and 
Development at age 60–64 with complete data.
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use was associated with greater odds of difficulty with stairs in the insufficient and deficient but not the normal 
25-hydroxyvitamin D groups when it was modelled categorically (Model B). There was no evidence of a statisti-
cally significant interaction when 25-hydroxyvitamin D was modelled continuously (see Fig. 2). These estimates 
were increasingly attenuated after adjustment for each set of covariates, although statin use remained associated 
with greater odds of difficulty with stairs in the fully adjusted model (Model E), both in the insufficient group 
(OR = 2.1, 95% CI 1.2 to 3.8, p = 0.012), and in the deficient group (OR = 2.1, 95% CI 1.2 to 3.5, p = 0.0051).
Difficulty gripping heavy objects. Neither statin use or 25-hydroxyvitamin D were associated with the odds of 
reporting difficulty gripping heavy objects in the sex-adjusted model, or in any subsequent regression model 
(Supplementary Table 1). There was weak evidence of an interaction between statin use and 25-hydroxyvitamin D 
(p = 0.093) such that in Model B statin use was associated with greater odds of difficulty gripping heavy objects in 
the insufficient group but not the deficient or the normal 25-hydroxyvitamin D groups. There was no evidence of 
Model A (Sex adjusted only)
Model B (Mutually adjusted 
with interaction)
Intrusive Body Pain
Model D = Model C + BMI 
& Knee OA
Model E = Model D + SEC, 
education & smoking†
Model C = Model 
B + inflammatory markers
OR 95% CI p value OR 95% CI p value OR 95% CI p value OR 95% CI p value OR 95% CI p value
Statin Use 1.7 (1.3,2.2) <0.001
25-hydroxyvitamin D
Overall effect 0.598
Normal >20 ng/l 1.0
Insufficient 13–20 ng/l 1.0 (0.8,1.3)
Deficient <13 ng/l 1.1 (0.9,1.4)
Statin Use (vs non use) by 25-hydroxyvitamin D (Interaction*)
Statin Use in those with 
Normal >20 ng/l 0.8 (0.5,1.4) 0.481 0.8 (0.5,1.3) 0.383 0.7 (0.4,1.3) 0.276 0.7 (0.4,1.2) 0.246
Statin Use in 
Insufficient 13–20 ng/l 2.6 (1.7,4.1) <0.001 2.5 (1.6,3.9) <0.001 2.0 (1.3,3.2) 0.002 1.9 (1.2,3.1) 0.005
Statin Use in 
Deficient<13 ng/l 1.8 (1.2,2.8) 0.004 1.8 (1.2,2.7) 0.006 1.5 (1.0,2.3) 0.059 1.4 (0.9,2.2) 0.106
IL6 (log pg/ml) 1.3 (1.1,1.5) 0.004 1.3 (1.1,1.5) 0.010 1.2 (1.0,1.5) 0.033
CRP (log mg/l) 1.3 (1.1,1.5) <0.001 1.2 (1.0,1.4) 0.028 1.2 (1.0,1.3) 0.060
BMI at 53 (per 1 kg/m2 
increase) 1.1 (1.0,1.1) <0.001 1.1 (1.0,1.1) <0.001
Knee OA at 53 (Yes 
vs No) 2.7 (1.9,4.0) <0.001 2.7 (1.8,4.0) <0.001
Sex (Men vs Women) 1.7 (1.4,2.1) <0.001 1.7 (1.4,2.1) <0.001 1.6 (1.3,2.0) <0.001 1.6 (1.3,2.0) <0.001
Table 2. Odds ratios of intrusive body pain by statin use and 25-hydroxyvitamin D status, adjusted for 
inflammatory markers, BMI, knee OA, education, SEC and smoking (n = 1556). †SEC, education & smoking 
not shown. •p-value = 0.003 for the interaction between statin use and 25-hydroxyvitamin D in Model B 
(formally tested using a likelihood ratio test comparing models with and without an interaction between 
25-hydroxyvitamin D and statin use).
Figure 1. Interaction between statin use and log 25-hydroxyvitamin D (modelled continuously) in association 
with intrusive body pain (p-value for interaction = 0.09).
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a statistically significant interaction when 25-hydroxyvitamin D was modelled continuously (see Supplementary 
Figure 1).
Chair Rise speed. Statin use and being in the lower 25-hydroxyvitamin D groups were associated with slower 
chair rise speed (see Table 4, Model A). The differences in chair rise speed were greatest in the insufficient and 
deficient 25-hydroxyvitamin D groups but there was no formal statistical evidence of an interaction when 
25-hydroxyvitamin D was modelled categorically (p = 0.32) or continuously. The associations were fully attenuated 
after adjustment for all the covariates; adjusting for BMI and knee OA reduced the estimates the most.
Model A (Sex adjusted only)
Model B (Mutually adjusted 
with interaction)
Difficulty going up stairs
Model D = Model C + BMI & 
Knee OA
Model E = Model D + SEC, 
education & smoking†
Model C = Model 
B + inflammatory markers
OR 95% CI p value OR 95% CI p value OR 95% CI p value OR 95% CI p value OR 95% CI p value
Statin Use 2.6 (1.9,3.5) <0.001
25-hydroxyvitamin D
Overall effect 0.003
Normal >20 ng/l 1.0
Insufficient 
13–20 ng/l 1.0 (0.7,1.5)
Deficient <13 ng/l 1.6 (1.2,2.3)
Statin Use (vs non use) by 25-hydroxyvitamin D (Interaction)
Statin Use in those 
with Normal 
>20 ng/l
1.4 (0.7,2.6) 0.292 1.3 (0.7,2.5) 0.378 1.2 (0.6,2.3) 0.586 1.1 (0.5,2.2) 0.749
Statin Use in 
Insufficient 
13–20 ng/l
3.6 (2.1,6.1) <0.001 3.4 (1.9,5.9) <0.001 2.4 (1.3,4.2) 0.003 2.1 (1.2,3.8) 0.012
Statin Use in 
Deficient <13 ng/l 2.7 (1.7,4.3) <0.001 2.8 (1.7,4.5) <0.001 2.2 (1.3,3.6) 0.003 2.1 (1.2,3.5) 0.005
IL6 (log pg/ml) 1.4 (1.1,1.7) 0.007 1.3 (1.0,1.7) 0.022 1.3 (1.0,1.6) 0.049
CRP (log mg/l) 1.6 (1.3,1.9) <0.001 1.4 (1.1,1.7) 0.001 1.3 (1.1,1.6) 0.006
BMI at 53 (per 
1 kg/m2 increase) 1.1 (1.1,1.1) <0.001 1.1 (1.1,1.1) <0.001
Knee OA at 53 (Yes 
vs No) 3.6 (2.4,5.3) <0.001 3.5 (2.3,5.3) <0.001
Sex (Men vs 
Women) 2.1 (1.6,2.9) <0.001 2.2 (1.6,2.9) <0.001 1.9 (1.4,2.6) <0.001 1.8 (1.3,2.5) <0.001
Table 3. Odds ratios of difficulty going up/down stairs by statin use and 25-hydroxyvitamin D status, adjusted 
for inflammatory markers, BMI, knee OA, education, SEC and smoking (n = 1556). †SEC, education & smoking 
not shown. *p-value = 0.078 for the interaction between statin use and 25-hydroxyvitamin D in Model B 
(formally tested using a likelihood ratio test comparing models with and without an interaction between 
25-hydroxyvitamin D and statin use).
Figure 2. Interaction effect of statin use and log 25-hydroxyvitamin D (modelled continuously) in association 
with difficulty going up/down stairs (p-value for interaction = 0.48).
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Grip strength. There was no association between statin use and grip strength in the sex adjusted model (dif-
ference in mean grip strength (kg) = −0.5, 95% CI −1.8 to 0.8, p = 0.4), or in any subsequent regression models 
(Supplementary Table 2). There was no evidence of an interaction between statin use and 25-hydroxyvitamin D 
on grip strength p = 0.59).
Sensitivity Analysis. There was no difference in prevalence estimates of statin use when comparing the 
sub-sample with complete data (n = 1556) (19.9%) with the larger sample for whom statin use and at least one 
muscle related outcome was known (n = 2380) (20.7%). While there were some differences between the analytical 
sample and the sample of study members who were assessed at age 60–64 but did not have complete data and so 
were excluded from our analyses (the analytical sample had better physical performance, slightly lower mean BMI 
and were more likely to have higher educational levels), the estimates from sex adjusted models rerun using the 
maximum available samples were similar to the estimates reported.
Discussion
In a nationally representative British population, statin use was associated in sex-adjusted models with increased 
odds of intrusive body pain and difficulty climbing stairs and with slower chair rise speed. The associations were 
strongest in those with insufficient or deficient 25-hydroxyvitamin D status. For chair rise speed, these associa-
tions were fully accounted for by inflammation, prior BMI, knee OA, smoking and SEC. For intrusive body pain 
and difficulties with stairs, there remained associations with statin use for those of insufficient and/or deficient 
25-hydroxyvitamin D status in fully-adjusted models.
Previous studies9–13,15–18 have typically focused on one or another of the broad range of adverse side effects 
of statins. We instead examined a range of chronic muscle related outcomes including proximal and distal limb 
function (both self-reported and performance-based), and intrusive pain. Importantly, consistent with others18, 
we find no association between statin use and grip strength. Muscle related disorders tend to affect the proximal 
rather than distal muscles50 adding biological plausibility to our results. Our results support the view that the 
relationship between 25-hydroxyvitamin D status and health outcomes is non linear and is subject to a threshold 
Model A (Sex adjusted only)
Model B (Mutually 
adjusted with interaction)
Chair Rise Speed/min
Model D = Model C + BMI 
& Knee OA
Model E = Model D + SEC, 
education & smoking†
Model C = Model 
B + inflammatory markers
Regression 
coefficient
95% 
CI p value
Regression 
coefficient
95% 
CI
p 
value
Regression 
coefficient
95% 
CI p value
Regression 
coefficient
95% 
CI p value
Regression 
coefficient
95% 
CI p value
Statin Use −1.7 (−2.7, −0.7) <0.001
25-hydroxyvitamin D
Overall effect 0.025
Normal > 20 ng/l 0
Insufficient 
13–20 ng/l −0.6
(−1.6, 
0.3)
Deficient 
<13 ng/l −1.3
(−2.3, 
−0.4)
Statin Use (vs non use) by 25-hydroxyvitamin D (Interaction)
Statin Use in 
those with 
Normal > 20 ng/l
−0.5 (−2.3, 1.4) 0.605 −0.4
(−2.2, 
1.5) 0.702 0.0
(−1.8, 
1.8) 0.968 0.1
(−1.7, 
1.8) 0.952
Statin Use in 
Insufficient 
13–20 ng/l
−2.3 (−4.0, −0.7) 0.006 −2.0
(−3.7, 
−0.4) 0.017 −1.3
(−2.9, 
0.4) 0.128 −1.0
(−2.6, 
0.7) 0.245
Statin Use 
in Deficient 
<13 ng/l
−1.8 (−3.4, −0.2) 0.023 −1.7
(−3.2, 
−0.1) 0.033 −1.0
(−2.5, 
0.5) 0.207 −0.8
(−2.3, 
0.7) 0.302
IL6 (log pg/ml) −0.9 (−1.6, −0.3) 0.004 −0.8
(−1.4, 
−0.2) 0.014 −0.7
(−1.3, 
−0.1) 0.027
CRP (log mg/l) −1.0 (−1.5, −0.5) <0.001 −0.7
(−1.2, 
−0.1) 0.013 −0.5
(−1.0, 
0.0) 0.058
BMI at 53 
(per 1 kg/m2 
increase)
−0.2 (−0.3, −0.1) <0.001 −0.2
(−0.3, 
−0.1) <0.001
Knee OA at 53 
(Yes vs No) −2.4
(−3.8, 
−1.1) <0.001 −2.2
(−3.6, 
−0.9) 0.001
Sex (Men vs 
Women) −1.0
(−1.8, 
−0.2) 0.010 −1.0
(−1.7, 
−0.2) 0.012 −0.9
(−1.6, 
−0.1) 0.026 −0.5
(−1.3, 
0.2) 0.179
Table 4. Difference in mean chair rise speed (stands/minute) by statin use and 25-hydroxyvitamin D status, 
adjusted for inflammatory markers, BMI, knee OA, education, SEC and smoking (n = 1556). †SEC, education & 
smoking not shown. *p-value = 0.32 for the interaction between statin use and 25-hydroxyvitamin D in Model 
B (formally tested using a likelihood ratio test comparing models with and without an interaction between 
25-hydroxyvitamin D and statin use).
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effect43. This is evidenced by the weaker or absence of an interaction between 25-hydroxyvitamin D status and 
statin use when 25-hydroxyvitamin D is modeled continuously rather than categorically. This is consistent with 
clinical recommendations which typically use a threshold for treatment.
For intrusive body pain, the associations with statin use were only apparent in those with insufficient 
25-hydroxyvitamin D status. These associations remained, albeit weakened, after adjustment for covariates. 
Previous cross sectional studies have suggested the involvement of 25-hydroxyvitamin D in statin related myal-
gia. Data from the NHANES, report greater myalgia in statin users in the low 25-hydroxyvitamin D groups23. 
However in a more select group of statin users - those who wished to switch to another statin - there did not 
appear to be an association between 25-hydroxyvitamin D status and myalgia51. In a small series of 128 patients25 
with statin induced myalgia, 25-hydroxyvitamin D was significantly lower in statin users than non users. 
Importantly, in this study, the statin induced myalgia responded to 25-hydroxyvitamin D replacement in 92% 
of the cases. It should be noted that low 25-hydroxyvitamin D status is itself a cause of myopathy and myalgia50.
There was weak evidence in this study, that statin use was associated with difficulty going up and down stairs 
only for those with insufficient and/or deficient 25-hydroxyvitamin D status. Again these associations were only 
partially explained by the covariates. Statin use was associated with poorer objective motor performance (as indi-
cated by slower chair rise speed) but the differences did not vary significantly across the 25-hydroxyvitamin D 
groups; and these associations were fully attenuated after adjustment for BMI, knee OA, smoking and SEC. There 
is conflicting evidence on whether statin use is associated with poor motor performance. Gray et al. found no dif-
ferences between statin users and non users in a battery of tests assessed repeatedly over six years including 6-min 
walk test performance, repeated chair stands and grip strength (before and after adjustment for age, ethnicity, edu-
cation, BMI, alcohol consumption, systolic and diastolic blood pressure, self-reported health, number of antihyper-
tensive medications, diabetes mellitus, depressive symptoms, history of CHD, and hormone trial participation)52. 
Statin use did not substantially increase decline in gait speed in community-dwelling older adults (before and after 
adjustment for demographic characteristics, health-related behaviors, health status, and access to health care53). 
Some studies, such as the Three City Cohort (French cities; Bordeaux, Dijon, and Montpellier), even find that sta-
tin users have better physical performance than non users54. Notably however, 25-hydroxyvitamin D (or inflam-
matory markers and previous knee OA and SEC) are not typically included in these studies. Small interventional 
studies suggest that 25-hydroxyvitamin D supplementation can ameliorate statin induced intolerance of myopa-
thy (and myalgia)55,56.
Given our findings, both the inverse associations between 25-hydroxyvitamin D status and certain 
muscle-related outcomes, and evidence that 25-hydroxyvitamin D status may modify the associations of statin 
use on these outcomes needs to be further investigated. Ideally a trial is required to address whether treatment of 
a low 25-hydroxyvitamin D prior to starting a statin prevents myalgia and any adverse change in proximal motor 
performance. Such studies may be redundant if a broader strategy to treat low 25-hydroxyvitamin D status in the 
general population is adopted. Pragmatically some would suggest that a low 25-hydroxyvitamin D is sufficient 
grounds for replacement given the pleiotropic effects 25-hydroxyvitamin D may have on other outcomes includ-
ing cognitive function, cardiac disease and bone41,57.
What are the implications for clinical practice? As stated above, a trial may be required but may be redundant 
if clinicians feel there is sufficient grounds to treat low 25-hydroxyvitamin D due to the broad health benefits43. 
While it is recognised that low 25-hydroxyvitamin D is a risk factor for statin related adverse side effects58,59, 
we are not aware of a consensus statement regarding best practice with regards to statin use. The first author’s 
personal practice (NS) is to check 25-hydroxyvitamin D when considering a statin – the timing of replacement 
and statin initiation depends on the clinical situation; and to check and replace 25-hydroxyvitamin D in patients 
who appear to be intolerant of statins or report chronic side effects. No doubt practice varies depending upon the 
setting (primary versus secondary care) and the patient population. Clinicians should be aware of the possible 
relationship between low 25-hydroxyvitamin D and adverse side effects of statin use, and investigate and treat 
based upon local practice and individual patient circumstances.
In RCTs, what constitutes a statin related adverse effect is poorly defined and varies between trials. In 26 
trials, broadly defined ‘muscle problems’ occurred in 12.7% of statin users versus 12.4% in the placebo group60. 
Trial data focus almost exclusively on the more acute side effects of statins (i.e., acute muscle inflammation): 
out of 42 trials, 16 do not even report the frequency of the more insidious chronic muscle problems. Only one 
trial asked about chronic muscle problems61. Trials may not be structured to identify these adverse effects. 
25-hydroxyvitamin D status is not typically considered in trials but one would expect low 25-hydroxyvitamin D 
status to be balanced across treatment and placebo groups. Nevertheless, it may be prudent for future statin trials 
to assess 25-hydroxyvitamin D status and incorporate it into the randomization process.
Another relevant aspect of RCTs is that patients with severe hypertension, chronic obstructive pulmonary dis-
ease (COPD), renal disease and poorly controlled diabetes are typically excluded; and these patients may be more 
likely to have low 25-hydroxyvitamin D status62–64. A strength of NSHD is that the sample includes individuals 
with a range of health conditions and remains broadly representative of the population born in mainland Britain 
straight after the second world war65. However, a third of participants had one or more missing variables which 
may have affected its representativeness, although the proportion of statin users and the associations we observed 
between statin and non statin users were similar in the maximum and the complete data samples. Further, statin 
use and 25-hydroxyvitamin D status was comparable to other representative samples of those in early old age66,67. 
Nevertheless, our findings need to be replicated in older and younger cohorts to see whether they are generaliza-
ble to the whole adult population.
Another strength of this study is that our sample was homogeneous for age which enabled us to examine 
associations free from the confounding effect of age. In samples heterogeneous for age, it is consistently found 
to be one of the strongest predictors of statin related adverse effects10,11. Given low 25-hydroxyvitamin D status 
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increases with age68 and is associated with telomere length69, further work is needed to explore whether this partly 
explains the age related association between statin use and muscle-related outcomes.
This study also has additional limitations. First, statin use was self-reported and we do not have informa-
tion on the type of statin, the dose or its duration. Second, we cannot directly assess pre and post statin func-
tion and cannot comment on acute adverse side effects such as myositis. Third, we do not have information on 
how many study members have tried and stopped statins in the past. Fourth, residual confounding may remain 
from unmeasured factors, especially as the covariates used did at least partly attenuate the associations observed 
between statin use and the muscle related outcomes.
In conclusion, we find that statin use was associated with a range of non acute muscle related outcomes 
in men and women in early old age. These associations were confined or more apparent in those with low 
25-hydroxyvitamin D status, and partly explained by other risk factors such as BMI and knee OA. Replication 
in older and younger populations is required given recent NICE guidelines that call for more widespread use of 
statins. Although a trial is required to determine if treatment of low 25-hydroxyvitamin D prevents statin related 
adverse effects, if there are clear clinical grounds for treating a low 25-hydroxyvitamin D then it may be reasona-
ble to do so before starting statin treatment. The recommendations from the UK Government 25-hydroxyvitamin 
D group are awaited.
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